Você está na página 1de 30

Case Study Test & Control

Group A3

August 8, 2016

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Objectives
What we were asked to do?

- SELECTION OF A CONTROL GROUP

- SELECTION OF CONTROL POOL

- IMPACT MEASUREMENT OF THE CAMPAIGN-DIGITAL MARKETING.

- FUTURE SCOPE

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Executive Summary
A quick glance on the data provided
TEST Group Data
Unique Physicians
829
MYRBETRIQ Rx Data for
months
Dec14 to Nov15
MYRBETRIQ Detailing Data for
months
Dec14 to Nov15
MYRBETRIQ Sampling Data for
months
Dec14 to Nov15
Market Brands Rx data for
months
Dec14 to Nov15
Physician Identifier- IMS ID
Other identifiers available:
Oabdecile, STATE, Target Flag,
Specialty Group

Test Group
Data

Control Group Data


Unique Physicians
926
MYRBETRIQ Rx Data for
months
Dec14 to Nov15
MYRBETRIQ Detailing Data for
months
Dec14 to Nov15
MYRBETRIQ Sampling Data for
months
Dec14 to Nov15
Market Brands Rx data for
months
Dec14 to Nov15
Physician Identifier- IMS ID
Other identifiers available:
Oabdecile, STATE, Target Flag,
Specialty Group

Control Group
Data
Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

Executive Summary
A quick glance on the Analysis done
Rx_Myrbetriq
800

Post-Campaign

Pre-Campaign

700

718.00

600

683.00
585.00

563.00

582.00

499.00
500

462.00

Rx

406.00

492.00

400

Test Post
Campaign

589.00

397.00
438.00

459.00
502.00

470.00
529.00

447.00
523.00

2786

457.00

386.00
429.00

453.00

IMPACT MEASUREMENT
Test Pre
2927
Campaign

446.00

398.00

A= Test Post- Pre Campaign


Control Post
Control Pre
Campaign
3199
Campaign

141
3001

B=Control Post-Pre Campaign

198

IMPACT=A-B

-57

300

200

100

0
Dec'14

Jan'15

Feb'15

Mar'15

Apr'15

May'15

Jun'15

Jul'15

Aug'15

Sep'15

Oct'15

Nov'15

Month
test

c3

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Understanding the Business Problem


What we understood about the given problem

Myrbetriq wants to know the effect of a digital marketing campaign for its drug.
To study the effect, a group of physicians is targeted for this campaign.
Test group is exposed to the campaign. Besides the effect of campaign, there should not
be any difference in the behavior of test and control group.
Out of given control groups, the control group which replicates the behavior of the test
group during the pre-campaign period, most closely, needs to be identified.
Impact of the campaign is to be calculated by taking the selected control group as the
base.

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly Restricted

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Assumptions ,Data Cleaning & Segmentation


Considered for our analysis

ASSUMPTIONS

DATA CLEANING

The campaign begins after the


end of month of May15 and
ends before start of June16.

Replacing Null values in


Detailing and Sampling data
with 0

There is no lag in effect of the


campaign, i.e. the effect of the
campaign is instantaneous.

Removing physician level data


having Myr_Rx data as NULL

Carry-over Effect is neglected.

Removing outlier data for Rx


sales for each test and control
group

SEGMENTATION
Categorizing Decile into 3
categories-

H: 8-10,
M: 4-7 and
L: 1-3
Categorizing the States into 4
regions:
Midwest
West
North-East
South
Unique ID using Decile, Specialty
Group and Region.

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

10

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Control Group Selection


Amongst the 3 given control groups, the control group most closely representing test group is selected

On the basis of categorical variables i.e. Specialty Group and Region, we


study the writing practice of physicians in test group and compare it with
those in control groups
For each Categorical Variable, we calculate the average Rx per physician
for both the control group and test group
The control group with minimum Euclidean distance or minimum error
variation is selected

*Source: Sales, Calls and Segmentation data provided AI

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

12

Continued
Amongst the 3 given control groups, the control group most closely representing test group is selected
Average_Rx_Market

Average_Rx_Myrbetriq

60

20

45.71
43.62
41.76

40

10

16.52
13.74
12.54
7.34

20.37
18.43
14.23

8.24
6.31
7.37

0
obg

5.00
6.92

7.59
6.96

0.75
other

pcp

urology

15.97
14.42352941
14.09

14

30
20

17.44

16

Average_Rx

Average_Rx

18

48.49

50

12
10
8 5.17
6

5.54

3.48

7.12
5.40

5.50
4.28

2.49
2.11

2
2.05

0
obg

other

Specialty Group
test

c1

c2

1.27
0.86

1.95 1.93

0.75

pcp

1.43
0.82

urology

Specialty Group
c3

test

c1

c2

c3

From the above graphs and by calculating Euclidean's Distance , we conclude that Control Group 3 is closest to test on the
basis of specialty group.
Refer Annexure for Euclidean Distance Calculation.

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

13

Continued
Amongst the 3 given control groups, the control group most closely representing test group is selected
Average_Rx_Market

Average_Rx_Myrbetriq

25

6.08
19.08
18.62
18.21

15

14.95
14.42

15.43

13.87
10

9.69

10.79

5.93
5.81

16.39
15.87

11.30
10.68

10.00

10.07
7.89

Average_Rx

Average_Rx

20

5.36
5.23

4.34

4.52
4
3.56

4.034.08
3.80

3.73

3.14

3.12

2.97
2.35

5
1
0

0
SOUTH

MID WEST

NORTH EAST

WEST

SOUTH

MID WEST

Region
TEST

C1

NORTH EAST

WEST

Region
C2

C3

TEST

C1

C2

C3

From the above graphs and by calculating Euclidean's Distance , we conclude that Control Group 3
is closest to test on the basis of Region
For Euclideans Distance Calculation, refer to annexure

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

14

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Control Pool Selection


From the selected control group, we select the subset or pool which closely represents the test group

Each Physician from Test is mapped on to physicians from


control group 3 on the basis of UID
This results in a one to many mapping.
The following parameters are considered for error
variation method:
Last 6 months Rx for Market, Last 3 month Rx for Market,
Last month Rx for Market,
Last 6 months Rx for Myrbetriq, Last 3 month Rx for
Myrbetriq, Last month Rx for Myrbetriq,
Last 6 months Detailing for Myrbetriq, Last 6 months
Sampling for Myrbetriq
After carrying out error variation method, we are left with
only one mapped physician in control group for one
physician in test group
We then apply cut-off on the average error to filter our
control pool

S.No Average_Error Conrol Pool Size


1

35%

374

45%

525

No Cut-Off

814

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

16

Control Pool Selection (Continued)


Control Pool Selected is mapped on Test Group to see the closeness in pre-campaign period at various error cut-off

ERROR CUT-OFF at 35%


Average_Rx_Myrbetriq
1
0.9

Post-Campaign

Pre-Campaign
0.88

0.8

0.84
0.72

0.69

Average_Rx

0.7

0.61
0.57

0.6
0.50

0.60

0.5
0.4

0.71

0.49
0.54

0.56

Feb'15

Mar'15

0.56
0.62

0.58
0.65

0.55
0.64

0.72
0.56

0.47
0.53

0.49

0.55

0.3
0.2
0.1

0
Dec'14

Jan'15

Apr'15

May'15

Jun'15

Jul'15

Aug'15

Sep'15

Oct'15

Nov'15

At 35% Error Cut-off, the


pool size is about 374
physicians.
On the Basis of these
physicians, the control
pool is mapped on to the
test group
We can see that, Rx in
control pool closely
represents the test group
in the pre-campaign period

Month

ERROR CUT-OFF= 35%


test

c3

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

17

Control Pool Selection (Continued)


Control Pool Selected is mapped on Test Group to see the closeness in pre-campaign period at various error cut-off

ERROR CUT-OFF at 45%


Average_Rx_Myrbetriq
0.7

0.63
0.49

0.5

0.45

0.46

0.41

Average_Rx

Post-Campaign

Pre-Campaign

0.6

0.43

0.58

0.53
0.59

0.47

0.49

0.48

0.47

0.48

0.4

0.39

0.45

0.46
0.40

0.37

0.35

0.2
0.1
0

Dec'14

Jan'15

Feb'15

Mar'15

Apr'15

May'15

Jun'15

Jul'15

Aug'15

Sep'15

Oct'15

Month

ERROR CUT-OFF= 45%


test

0.50

0.41

0.39
0.3

0.63

Nov'15

At 45% Error Cut-off, the pool


size is about 525 physicians.
On the Basis of these
physicians, the control pool is
mapped on to the test group
We can see that, Rx in control
pool closely represents the
test group in the precampaign period but the gap
between test and control
group is more pronounced in
45% error cut-off

c3

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

18

Control Pool Selection (Continued)


Control Pool Selected is mapped on Test Group to see the closeness in pre-campaign period at various error cut-off

No ERROR CUT-OFF
Average_Rx_Myrbetriq

0.6

Post-Campaign

Pre-Campaign
0.5
0.41

0.40

0.4

Average_Rx

0.41

0.45

0.36
0.32
0.33
0.28

0.29

Dec'14

Jan'15

0.37

0.35

0.34

0.38

0.3

0.47

0.45

0.44
0.49

0.30

0.34
0.31

0.35

0.36
0.31

0.30

0.2

0.1

0
Feb'15

Mar'15

Apr'15

May'15

Jun'15

Month
test

Jul'15

Aug'15

Sep'15

Oct'15

Nov'15

At No Error Cut-off, the pool


size is about 814 physicians.
On the Basis of these
physicians, the control pool is
mapped on to the test group
We can see that, Rx in control
pool closely represents the
test group in the precampaign period but the gap
between test and control
group is maximum in no error
cut-off

c3

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

19

Control Pool Selection (Continued)


Control Pool Selected is mapped on Test Group to see the closeness in pre-campaign period in sampling and detailing

Average Sampling & Detailing


6 Months Sampling & Detailing
5
4.54
4.33

4.5
4

Average

3.5
3

2.5
2

The histograms show the close


mapping of control group on test
group in term of average detailing
and sampling.
Similar Detailing and sampling in
control and test

1.58

1.54
1.5
1
0.5
0
Sampling

Detailing

Test

C3

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

20

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Control Pool Representation


The test pool selected should be representative of the entire test target

Specialty

Target %

Test %

OBG

3%

1%

UROLOGY

9%

6%

87%

92%

1%

1%

PCP
OTHERS
Region
MID WEST
NORTH EAST
SOUTH
WEST

Target %
28%
14%
41%
17%

Test %
27%
15%
42%
15%

We check that the selected test pool is


representative of the entire test target
on the basis of categorical variables
On the basis of Specialty Group, the test
pool is close enough representative of
the test group
On the basis of Regionthe test pool is
close enough representative of the test
group

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

22

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Campaign Impact Measurement


Calculation of the effect of campaign on the Rx of Myrbtriq
Rx_Myrbetriq
800

Post-Campaign

Pre-Campaign

700

Test Post
Campaign

718.00

600

683.00
585.00

563.00

462.00

Rx

406.00

492.00

400

457.00

3001

446.00

B=Control Post-Pre Campaign

198

IMPACT=A-B

-57

589.00

500
397.00
438.00

459.00
502.00

470.00
529.00

447.00
523.00
386.00
429.00

453.00

2786

A= Test Post- Pre Campaign


Control Post
Control Pre
Campaign
3199
Campaign

582.00

499.00

IMPACT MEASUREMENT
Test Pre
2927
Campaign

141

398.00
300

200

PRE Campaign Post Campaign


Market Share
%
%

100

0
Dec'14

Jan'15

Feb'15

Mar'15

Apr'15

May'15

Jun'15

Month
test

c3

Jul'15

Aug'15

Sep'15

Oct'15

Nov'15

Test

26

27.6

Control

31.6

31.2

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly
Restricted

24

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Further Insights
What more could have been done?

The Null values could have been replaced by its decile averages.
Instead of choosing from 3 groups, an entire new group can be created from
the combined pool of 3 which will have better matching characteristics
The deciling can be done on the basis of detailing and sample drops and take
them as categorical variable.
During the error calculation process, weights can be assigned to different
parameters.
During error calculation, small changes resulting in large error can be avoided

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly Restricted

26

Agenda
Section 1: Objectives
Section 2: Executive Summary

Section 3: Understanding the Business Problem


Section 4: Assumptions, Data Cleaning &
Segmentation
Section 5: Control Group Selection

Section 6: Control Pool Selection


Section 7: Control Pool Representation
Section 8: Campaign Impact Measurement
Section 9: Further Insights
Section 10: Annexure

Annexure
Writing on Basis of Specialty Group
Market
obg
urology
pcp
other

Euclidean
Distance

test
7.344828
41.76056
6.955556
0.75
2.054054

c1
12.53968
48.49333
7.588435
20.37209
6.918033

c2
16.51852
43.61875
8.239796
18.42857
5

c3
13.74074
45.71176
7.365108
14.22642
6.311475

21.94088 20.26004 16.01333

Myrbetriq
test
c1
c2
c3
obg
3.482759 5.396825 5.537037 5.166667
urology 17.43662 15.97333 14.09375 14.42353
pcp
2.111111 1.926871 2.494898 1.947842
other
0.75
7.116279
5.5
4.283019
1.27027 1.42623 0.857143 0.819672
Euclidean
Distance

6.811214 6.186704 4.962477

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly Restricted

28

Annexure
Writing on Basis of Region
Myrbetriq
SOUTH

TEST

C1

C2

C3

Market

3.564955 5.81372549 6.083333

5.929293

MID WEST 3.798283 4.34351145 4.082609


NORTH
5.35877862
EAST
3.72807
6
5.229412
3.12135922
WEST
2.347826
3
2.974359

4.029536

Euclidean
Distance

2.93458812
9
3.011585

4.519774
3.142077

2.627014

TEST

C1
18.620915
SOUTH
9.694864
03
14.419847
MID WEST 10.7897
33
NORTH
16.389312
EAST
10
98
10.684466
WEST
7.891304
02
Euclidean
11.894428
Distance
0
58

C2

C3

19.08333

18.20539

13.86957

14.94515

15.87059

15.42938

10.06667

11.29508

11.69722

11.43506

Copyright 2016 Axtria and/or its affiliates. All rights reserved. | Axtria Confidential Internal/Restricted/Highly Restricted

29

Você também pode gostar